中文别名: |
阿托伐他汀内酯;(4R,6R)-6-{2-[2-(4-氟苯基)-5-异丙基-3-苯基-4-(苯基氨基甲酰基)吡咯-1-基]乙基}-4-羟基四氢-2H-吡喃-2-酮;5-(4-氟苯基)-2-(1-甲基-乙基)-N,4-二联苯-1-[2-[(2R,4R)-四氢-羟基-6-氧代-2H-吡喃-2-yl]乙基]-1H-吡咯-3-羧酸胺盐;阿伐他汀钙内酯;阿托伐他汀-D5内酯;阿托伐他汀钙杂质 D;阿托伐他汀钙杂质H(EP) 标准品;阿托伐他汀内酯(阿托伐他汀EP杂质H);阿托伐他汀内酯标准品;阿托伐他汀中间体L-6;氨曲南-D5;直接兰80;阿托伐他汀钙杂质H;5-(4-氟苯基)-1-[2-[(2R,4R)-4-羟基-6-氧代四氢-2H-吡喃-2-基]乙基]-2-异丙基-N,4-二苯基-1H-吡咯-3-甲酰胺;阿托伐他汀相关化合物H;阿托伐他汀内脂;阿托伐他汀杂质H;阿托伐他汀EP杂质H;阿托伐他汀D5硫丹内酯;阿托伐他汀钙EP杂质H;5-(4-氟苯基)-2-(1-甲基-乙基)-N,4-二联苯-1-[2-[(2R,4R)-四氢-羟基-6-氧代-2H-吡喃-2-YL]乙基]-1H-吡咯-3-羧酸胺盐 |
英文别名: |
Atorvastatin lactone;(4R,6R)-6-{2-[2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrol-1-yl]ethyl}-4-hydroxytetrahydro-2H-pyran-2-one;Atorvastatin Lactone L-6;ATORVASTATIN-D5 LACTONE;Atorvastatin EP Imp H;Atorvastatin EP Impurity H;Benzeneacetamide,a-cyano-4-methoxy;5-(4-Fluorophenyl)-1-{2-[(2R, 4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-2-isopropyl-N,4-diphenyl-1H-pyrrole-3-carboxamide;Lactone Impurity, 5-(4-Fluorophenyl)-1-{2-[(2R, 4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-2-isopropyl-N,4-diphenyl-1H-pyrrole-3-carboxamide;Atorvastatin Related Compound H;5-(4-Fluorophenyl)-1-[2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl]-2-isopropyl-N,4-diphenyl-1H-pyrrole-3-carboxamide;Atorvastatin d-Lactone;Atorvastatin Impurity H;(RS) Atorvastatin Lactone;Atorvastatin EPIMp H (USP RCH);Atorvastatin Calcium Impurity D;Diepoxide Atorvastatin Lactone Diepoxide;1-[2-[[(2R)-Tetrahydro-4β-hydroxy-6-oxo-2H-pyran]-2α-yl]ethyl]-5-(4-fluorophenyl)-2-isopropyl-4,N-diphenyl-1H-pyrrole-3-carboxamide;ATORVASTATIN LACTONE;Atorvastatin EP IMpurity H;ATORVASTATIN LACTONE [MI];MLS006010799;(2R-trans)-5-(4-fluorophenyl)-2-(1-methylethyl)-N,4-diphenyl-1-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)-ethyl]-1H-pyrrole-3-carboxamide;5-(4-fluorophenyl)-1-[2-((2R,4R)4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide;5-(4-fluorophenyl)-1-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-N,4-diphenyl-2-propan-2-ylpyrrole-3-carboxamide;DTXSID90155033;5-(4-fluorophenyl)-1-(2-((2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-2-isopropyl-N,4-diphenyl-1H-pyrrole-3-carboxamide;(2R-Trans)-5-(4-fluorophenyl)-2-(1-methyl -ethyl)-N,4-diphenyl-1-[2-(tetrahydro-4-hydroxy-6-oxo -2H-pyran-2-yl)ethyl]-1H-pyrrole-3-carboxamide;(2R-trans)-5-(4-fluorophenyl)-2-(1-methylethyl)-N,4-diphenyl-1-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)-ethyl]1H-pyrrole-3-carboxamide;(2R-trans)-5-(4-fluorophenyl)-2-(1-methylethyl)-N,4-diphenyl-1-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole-3-carboxamide;5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran -2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide;ATORVASTATIN .DELTA.-LACTONE;ATORVASTATIN CALCIUM IMPURITY H [EP IMPURITY];AKOS015896169;DTXCID4077524;5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy -6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide;C33H33FN2O4;UNII-7876IL7J2N;5-(4-Fluoro-phenyl)-1-[2-(4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide;(2R-trans)-5-(4-fluorophenyl)-2-(1-methylethyl)-N,4-diphenyl-1-[2-(tetrahydro-4-hydroxy-6-oxo2H-pyran-2-yl)ethyl]-1H-pyrrole-3-carboxamide;J-005315;Q27074604;(2R-trans)-5-(4-fluorophenyl)-2-(1-methyl-ethyl)-N,4-diphenyl-1-[2-(tetrahydro-4-hydroxy-6-o... |